Trial · NCT06990854
Electroacupuncture for PHN: Efficacy and Biomarker Evaluation in a Multicenter, Randomized, Sham-Controlled Trial Protocol
NCT06990854, Not applicable, Not yet recruiting, Dexiong Han
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Electroacupuncture for PHN: Efficacy and Biomarker Evaluation in a Multicenter, Randomized, Sham-Controlled Trial Protocol. Trials, record NCT06990854. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06990854
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Electroacupuncture for PHN: Efficacy and Biomarker Evaluation in a Multicenter, Randomized, Sham-Controlled Trial Protocol
- NCT number
- NCT06990854
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 207 participants, estimated
- Lead sponsor
- Dexiong Han
- Conditions
- Postherpetic Neuralgia ( PHN )
- Interventions
Electroacupuncture (Hans-100A, Nanjing Jisheng Medical Technology, China), Pharmacotherapy：① Pregabalin ( Lyrica™ ，Pfizer Inc. America) ② Methylcobalamin ( Mecobalamin tablets， Weicai (China) Pharmaceutical Co., Ltd， China）, Streitberger Placebo Needle Set ( Asiamed )
- First posted
- 2025-05-25
- Last updated
- 2025-07-09
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Assessing the participants' pain intensity by the Numerical Rating Scale | Assessments were performed at baseline and at the end of weeks 1, 2, 3, and 4 of treatment. | Pain intensity was assessed using the Numerical Rating Scale (NRS), an 11-point scale ranging from 0 ("no pain") to 10 ("intolerable pain"). This validated tool demonstrates rapid clinical utility and robust psychometric properties, including good reliability and validity in pain assessment. |
| Secondary | The number of pain episodes in the past 24 hours | Assessments were performed at baseline and at the end of weeks 1, 2, 3, and 4 of treatment. | Daily documentation of pain episodes over 24-hour intervals to characterize symptom fluctuation patterns. |
| Secondary | Psychological Status Assessment: Hamilton Anxiety Scale 36 ( HAMA ) | Assessments were performed at baseline and at the end of weeks 1, 2, 3, and 4 of treatment. | Hamilton Anxiety Scale36 (HAMA): A 14-item clinician-administered tool evaluating anxiety severity across domains such as anxious mood, tension, and insomnia. Scores ≥14 indicate clinically significant anxiety. |
| Secondary | Psychological Status Assessment: Hamilton Depression Scale37 (HAMD-21) | Assessments were performed at baseline and at the end of weeks 1, 2, 3, and 4 of treatment. | Hamilton Depression Scale37 (HAMD-21): A 21-item instrument assessing core depressive symptoms spanning affective, cognitive, and somatic dimensions. Assessments were performed at baseline and at the end of weeks 1, 2, 3, and 4 of treatment. |
| Secondary | The health-related quality of participants' life is assessed by The Short-Form 36 Health Survey | Assessments were performed at baseline and at the end of weeks 1, 2, 3, and 4 of treatment. | The Short-Form 36 Health Survey (SF-36) quantified health-related quality of life across 8 domains (e.g., physical function, social role). This instrument has been extensively validated in chronic pain research. |
| Secondary | Neuroregeneration Indicators: Neuropeptide Y (NPY) | Assessments were performed at baseline and at the end of weeks 1, 2, 3, and 4 of treatment. | Neuropeptide Y (NPY) , a mediator of neuro-immune crosstalk and synaptic remodeling. |
| Secondary | Neuroregeneration Indicators: Substance P (SP) | Assessments were performed at baseline and at the end of weeks 1, 2, 3, and 4 of treatment. | Substance P (SP), a tachykinin modulating nociceptive signaling. |
| Secondary | Inflammatory Markers : TNF-α | Assessments were performed at baseline and at the end of weeks 1, 2, 3, and 4 of treatment. | TNF-α, a proinflammatory cytokine. |
| Secondary | Inflammatory Markers : IL-10 | Assessments were performed at baseline and at the end of weeks 1, 2, 3, and 4 of treatment. | IL-10, an anti-inflammatory cytokine. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41199896 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06990854
GET https://conductscience.org/api/trials/v1/NCT06990854/registered